drugset / Trial / NCT01468467
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to define a safe dose of AC220 when given as maintenance therapy after treatment with an allogeneic stem cell transplant.
Timeline
- Start
- 2012-04
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quizartinib | Small molecule | — | Oral |